GlassScriptPhysician profile
Robert Lagrou
NPI 1629279351
$267,332.33
in general payments reported to CMS, 2019-2025
27 companies · $114K in 2025
The $114K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,473 · 2020: $399 · 2021: $379 · 2022: $639 · 2023: $59K · 2024: $90K · 2025: $114K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $194K · Honoraria: $35K · Travel and Lodging: $22K · Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $193,997.50 |
| Honoraria | $34,925.00 |
| Travel and Lodging | $21,646.16 |
| Food and Beverage | $12,873.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $170,812.57 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $89,442.07 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $1,043.39 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,010.86 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $807.08 | 2023-2025 | Auvelity |
| Alkermes, INC. | $655.02 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $570.99 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $412.27 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $402.66 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neuronetics, INC. | $333.03 | 2019-2023 | Neurostar Tms Therapy System |
| E.R. Squibb & Sons, L.L.C. | $300.79 | 2024-2025 | Cobenfy |
| Corium, LLC | $289.68 | 2022-2025 | Azstarys, Azstarys |
| Allergan, INC. | $273.69 | 2019-2020 | |
| Lundbeck LLC | $242.32 | 2019-2025 | Rexulti |
| Indivior INC. | $159.52 | 2019-2024 | Perseris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $115.26 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $90.34 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $87.56 | 2019 | |
| Ironshore Pharmaceuticals INC. | $80.66 | 2019-2022 | |
| Shire North American Group INC | $41.83 | 2019 | |
| Idorsia Pharmaceuticals US INC | $37.74 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $33.65 | 2025 | Jornay Pm |
| Livanova USA, INC. | $26.05 | 2022-2023 | Vns Therapy Symmetry Model 8103 Generator |
| Owp Pharmaceuticals, INC. | $17.78 | 2025 | Subvenite |
| Tempus Ai, INC | $16.20 | 2024 | |
| Sage Therapeutics, LLC | $15.28 | 2025 | Zurzuvae |
| Noven Therapeutics, LLC | $14.04 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lagrou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.